Skip to main content
. Author manuscript; available in PMC: 2014 Dec 1.
Published in final edited form as: Endocr Relat Cancer. 2014 May 6;21(3):435–442. doi: 10.1530/ERC-14-0107

Figure 5. 2-DG re-sensitizes cells to enzalutamide treatment.

Figure 5

(A) Cell morphology of LNCaP-p52 cells was shown after two days treatment with 2-DG in combination with or without enzalutamide. Vehicle control and 2-DG treatment were shown in top panel. Enzalutamide and combination treatment with 1 mM 2-DG were shown in bottom panel. Right panel: Cell growth after two days of treatment. All numbers were normalized to vehicle group. Data were presented in mean±SD in at least three independent experiments. (B) Glucose consumption (left), ATP production (middle), and lactate production (right) in C4-2B MDVR enzalutamide-resistant cells compared to parental C4-2B enzalutamide-sensitive cells. (C) 2-DG re-sensitizes C4-2B MDVR enzalutamide-resistant cells' response to enzalutamide treatment. Cell numbers were normalized to vehicle group. Data were presented in mean±SD in three independent experiments; *, p < 0.05, **, p < 0.01.